Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2005049020) USE OF 1-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/049020 International Application No.: PCT/HR2004/000055
Publication Date: 02.06.2005 International Filing Date: 19.11.2004
IPC:
A61K 31/428 (2006.01) ,A61K 31/429 (2006.01) ,A61K 31/4439 (2006.01) ,A61K 31/55 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
428
condensed with carbocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
429
condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
4427
containing further heterocyclic ring systems
4439
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
Applicants:
MERCEP, Mladen [HR/HR]; HR (UsOnly)
MESIC, Milan [HR/HR]; HR (UsOnly)
MODRIC, Marina [HR/HR]; HR (UsOnly)
PESIC, Dijana [HR/HR]; HR (UsOnly)
KIDEMET, Davor [HR/HR]; HR (UsOnly)
PLIVA-ISTRAZIVACKI INSTITUT D.O.O. [HR/HR]; Prilaz baruna Filipovica 29 10000 Zagreb, HR (AllExceptUS)
Inventors:
MERCEP, Mladen; HR
MESIC, Milan; HR
MODRIC, Marina; HR
PESIC, Dijana; HR
KIDEMET, Davor; HR
Common
Representative:
PLIVA - ISTRAZIVACKI INSTITUT D.O.O.; PRAVNI I PATENTNI POSLOVI Prilaz baruna Filipovica 29 10000 Zagreb, HR
Priority Data:
P20030957A21.11.2003HR
Title (EN) USE OF 1-THIA-DIBENZO[E,H]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
(FR) UTILISATION DE 1-THIA-DIBENZO[E,H]AZULENES POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT ET A LA PREVENTION DES MALADIES ET DES TROUBLES DU SYSTEME NERVEUX CENTRAL
Abstract:
(EN) The present invention relates to the use of derivatives from the group of 1-thia-3-aza­dibenzo[e,h]azulenes and of their pharmaceutically acceptable salts and solvates for the manufacture of a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.
(FR) L'invention concerne l'utilisation de dérivés de groupe des 1-thia-3-aza-dibenzo[e,h]azulènes et de leurs sels et solvates pharmaceutiquement acceptables pour la préparation d'une composition pharmaceutique destinée au traitement et à la prévention des maladies, des lésions, et des troubles du système nerveux central (SNC) causés par des troubles de l'équilibre neurochimique des amines biogéniques ou d'autres neurotransmetteurs.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)